我国省级基本药物增补情况与影响因素分析

Analysis of Supplementary Provincial Essential Drugs and Their Influential Factors in China

目的:探讨我国省级基本药物增补情况和影响因素,为新版国家基本药物目录的遴选与调整工作提供参考。方法:对全国31个省(市、自治区)增补基本药物目录的治疗类别和药品通用名进行比对分析和频数统计,对可能的影响因素进行相关性检验和比对分析,并对部分品种进行临床评价。结果:我国31个省(市、自治区)增补药品数量从64～410种不等,差异较大;增补药品集中度较差,只有1个省增补的品种占所有增补品种的50%左右;12个省增补了抗肿瘤药类别;有超过21个省(市、自治区)增补了西咪替丁等21种药品。结论:增补药品数量与当地经济发展水平存在一定的相关性,仅有不超过5%的增补药品属于非"医保"目录品种,因此增补药品集中度差根本上源于各省"社保"目录差异较大。

OBJECTIVE： To analyze supplementary provincial essential drugs and their influential factors in China, to provide reference for selecting and revising of new list of essential drugs. METHODS ： The specific treatment category and drugs＇ general name of supplementary list were analyzed in 31 provinces （cities, regions） using frequency and comparison methods. The correla- tion test and comparative analysis were conducted for potential influencing factors, and clinical evaluation was carried out for some types. RESULTS： The number of supplementary drugs in 31 provinces （cities, regions） was 64-410, which is large difference to each other; almost 50% of the drugs were selected by only 1 province; 12 provinces chose the antineoplastic drug, and 21 drugs were selected by more than 21 provinces, such as Cimetidine. CONCLUSION： The number of supplementary drugs is related to the GDP; more than 95% drugs belong to reimbursement list, and the poor concentration of the drugs in provincial essential drugs is resulted from significant diversity of reimbursement lists in nrovines.